# A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

> **NCT02039089** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** E2006 2.5 mg
- **DRUG:** E2006 10 mg
- **DRUG:** E2006 25 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02039089
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039089, "A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02039089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*